

# **Cytogenetics**

## **Technologies, Companies & Markets**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**November 2021**

**A Jain PharmaBiotech Report**

## AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 490 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1200 articles by 450 authors. These articles are updated on a yearly basis.

Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2018) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

## ABOUT THIS REPORT

This report will cover cytogenetics using the broad scope of cytogenetic analysis that extends beyond the simple description of the chromosomal status of a genome and enables the study of basic problems such as the nature of inherited syndromes, the genomic changes that are involved in tumorigenesis and the 3D organization of the human genome. It will include conventional FISH as well as cutting edge new technologies for molecular cytogenetics. Companies developing various technologies and the markets for these will be described.

**November 2021**  
**Copyright © 2021 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:** +4161-6924461  
**Email:** [info@pharmabiotech.ch](mailto:info@pharmabiotech.ch)  
**Web site:** <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold, or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

|  |           |
|--|-----------|
| <b>0. Executive Summary .....</b>                                      | <b>10</b> |
| <b>1. Introduction .....</b>   | <b>12</b> |
| <b>Definitions .....</b>   | <b>12</b> |
| <b>Historical evolution of cytogenetics .....</b>                      | <b>12</b> |
| <b>Scope of cytogenetics .....</b>                                     | <b>13</b> |
| <b>Molecular cytogenetics .....</b>                                    | <b>14</b> |
| <b>Basics of molecular biology relevant to cytogenetics .....</b>      | <b>14</b> |
| DNA .....  | 14        |
| RNA .....  | 15        |
| DNA transcription.....   | 15        |
| Chromosomes .....  | 15        |
| Mitochondrial DNA .....  | 16        |
| Genes.....   | 16        |
| <i>The genetic code.....</i>   | <i>16</i> |
| <i>Gene expression .....</i>   | <i>17</i> |
| The human genome .....   | 17        |
| Variations in the human genome.....                                    | 18        |
| <i>Variations in DNA sequences .....</i>                               | <i>18</i> |
| <i>Single nucleotide polymorphisms .....</i>                           | <i>18</i> |
| <i>Copy number variations in the human genome.....</i>                 | <i>18</i> |
| <i>Genotype and haplotypes.....</i>                                    | <i>20</i> |
| <i>Complex chromosomal rearrangements .....</i>                        | <i>20</i> |
| <i>Insertions and deletions in the human genome.....</i>               | <i>20</i> |
| <i>Large scale variation in human genome .....</i>                     | <i>21</i> |
| <i>Structural variations in the human genome .....</i>                 | <i>21</i> |
| <i>Replication of the DNA helix .....</i>                              | <i>22</i> |
| <i>Transposons.....</i>  | <i>22</i> |
| Mapping and sequencing of structural variation from human genomes..... | 23        |
| <b>2. Technologies used for cytogenetics .....</b>                     | <b>24</b> |
| <b>Introduction .....</b>  | <b>24</b> |
| <b>Quantitative fluorescent polymerase chain reaction .....</b>        | <b>24</b> |
| <b>RNA interference and cytogenetics .....</b>                         | <b>25</b> |
| RNA-induced transcriptional silencing complex.....                     | 25        |
| RNAi and cancer cytogenetics.....                                      | 25        |
| Single cell genetics by siRNA ablation .....                           | 26        |
| Role of miRNAs in cancer cytogenetics.....                             | 26        |
| <b>Preimplantation genetic diagnosis.....</b>                          | <b>26</b> |
| Preimplantation genetic haplotyping .....                              | 27        |
| <b>Bioinformatics and cytogenetics .....</b>                           | <b>27</b> |
| FISH probe design software .....                                       | 27        |
| LS-CAP algorithm.....  | 28        |
| Distance-based clustering of CGH data .....                            | 28        |
| <b>3. Fluorescent In Situ Hybridization .....</b>                      | <b>30</b> |
| <b>Introduction .....</b>  | <b>30</b> |
| <b>Innovative FISH technologies.....</b>                               | <b>32</b> |
| Automation of FISH.....  | 32        |
| Chromogenic in situ hybridization (CISH).....                          | 32        |
| Direct visual in situ hybridization .....                              | 33        |
| Direct labeled Satellite FISH probes.....                              | 33        |
| Fiber FISH.....  | 33        |
| FISH with telomere-specific probes .....                               | 33        |
| High-throughput quantitative FISH.....                                 | 34        |
| In vivo FISH.....  | 34        |
| Interphase FISH .....  | 35        |
| Intron chromosomal expression FISH .....                               | 35        |
| Multicolor FISH .....  | 35        |
| <i>Multicolor chromosome banding.....</i>                              | <i>36</i> |
| Oligonucleotide FISH .....   | 36        |
| peT-FISH™ .....  | 37        |
| Primed in situ labeling .....  | 37        |
| RNA-FISH .....   | 37        |
| Single copy FISH probes .....  | 38        |
| Use of peptide nucleic acid with FISH .....                            | 38        |
| Use of locked nucleic acids with FISH .....                            | 40        |

|  |           |
|--|-----------|
| <b>Applications of FISH .....</b>  | <b>40</b> |
| <b>Companies involved in FISH diagnostics .....</b>                              | <b>41</b> |
| <b>4. Genomic Technologies relevant to Cytogenetics .....</b>                    | <b>42</b> |
| <b>Introduction .....</b>  | <b>42</b> |
| <b>Karyotyping based on sequencing .....</b>                                     | <b>42</b> |
| <b>Microarrays/biochips for cytogenetics .....</b>                               | <b>42</b> |
| Microarrays vs karyotyping .....   | 43        |
| Tissue microarrays .....   | 43        |
| Chromosome copy number analysis .....  | 43        |
| Combination of FISH and gene chips .....   | 44        |
| Combination of CGH+SNP microarrays .....   | 44        |
| SignatureChip® .....   | 45        |
| <b>Molecular Combining .....</b>   | <b>45</b> |
| <b>High density oligonucleotide arrays .....</b>                                 | <b>45</b> |
| <b>Next Generation Screening® .....</b>  | <b>46</b> |
| <b>Comparative genomic hybridization .....</b>                                   | <b>46</b> |
| Array-based comparative genomic hybridization .....                              | 48        |
| aCGH vs karyotyping .....  | 48        |
| Comparison of array CGH and multipoint FISH .....                                | 49        |
| Combined use of tissue microarrays and aCGH .....                                | 49        |
| Single-cell array CGH .....  | 50        |
| Regulatory requirements for array CGH .....                                      | 50        |
| Future prospects of aCGH .....   | 50        |
| <b>Whole genome expression microarrays .....</b>                                 | <b>51</b> |
| Life Technologies Expression Array System .....                                  | 51        |
| Arrayit's® H25K .....  | 52        |
| CytoScan® HD Array .....   | 52        |
| Optical Mapping .....  | 52        |
| <b>Single cell cytogenetics .....</b>  | <b>53</b> |
| Single cell PCR .....  | 53        |
| LATE-PCR .....   | 53        |
| AmpliGrid-System .....   | 53        |
| Digital Counting .....   | 54        |
| Analysis of single-cell gene expression .....                                    | 54        |
| Fluorescent <i>in situ</i> RNA sequencing .....                                  | 55        |
| Application of single cell cytogenetics in preimplantation genetic testing ..... | 55        |
| <b>Direct molecular analysis without amplification .....</b>                     | <b>56</b> |
| <b>5. Molecular Imaging &amp; Single Molecular Detection .....</b>               | <b>58</b> |
| <b>Molecular imaging .....</b>   | <b>58</b> |
| Companies involved in molecular imaging .....                                    | 58        |
| <b>Single molecule detection .....</b>   | <b>59</b> |
| Spectrally resolved fluorescence lifetime imaging microscopy .....               | 59        |
| Single-molecule fluorescence resonance energy transfer .....                     | 60        |
| Confocal laser scanning .....  | 60        |
| Single Molecule Array .....  | 60        |
| PCR systems for single molecule detection .....                                  | 61        |
| Real-time PCR .....  | 61        |
| Digital PCR .....  | 61        |
| Emulsion PCR .....   | 62        |
| Rolling circle amplification technology .....                                    | 62        |
| Microfluidic assay for protein expression at the single molecule level .....     | 62        |
| Bioinformatic and single molecule detection .....                                | 63        |
| <b>6. Role of Nanobiotechnology in Cytogenetics .....</b>                        | <b>64</b> |
| <b>Introduction .....</b>  | <b>64</b> |
| <b>Nanobiology and the cell .....</b>  | <b>64</b> |
| <b>Visualization on nanoscale .....</b>  | <b>65</b> |
| Application of AFM for biomolecular imaging .....                                | 65        |
| Future insights into biomolecular processes by AFM .....                         | 65        |
| Use of AFM for microdissection of chromosomes .....                              | 66        |
| Scanning probe microscopy .....  | 66        |
| Near-field scanning optical microscopy .....                                     | 66        |
| Multiple single-molecule fluorescence microscopy .....                           | 67        |
| Nanoscale scanning electron microscopy .....                                     | 67        |
| Nanotechnology-based FISH .....  | 67        |
| Study of chromosomes by atomic force microscopy .....                            | 67        |
| Quantum dot FISH .....   | 67        |
| Nanobiotechnology for single molecule detection .....                            | 68        |
| Nanolaser spectroscopy for detection of cancer in single cells .....             | 69        |

|   |           |
|---|-----------|
| Carbon nanotube transistors for genetic screening .....                       | 69        |
| Quantum-dots-FRET nanosensors for single molecule detection .....             | 70        |
| 3D single-molecular imaging by nanotechnology .....                           | 70        |
| Manipulation of DNA sequence by use of nanoparticles .....                    | 70        |
| Nanofluidic/nanoarray devices to detect a single molecule of DNA .....        | 70        |
| Nanopore technology .....   | 71        |
| Portable nanocantilever system for diagnosis .....                            | 71        |
| Nanobiosensors .....  | 72        |
| <b>7. Biomarkers and Cytogenetics .....</b>                                   | <b>74</b> |
| <b>Introduction .....</b>   | <b>74</b> |
| Definitions .....   | 74        |
| Biomarkers and cytogenetics .....   | 74        |
| <b>Cancer biomarkers .....</b>  | <b>74</b> |
| Technologies for detection of cancer biomarkers .....                         | 75        |
| Telomerase as a biomarker of cancer .....                                     | 75        |
| Digital karyotyping for cancer biomarkers .....                               | 75        |
| Optical systems for in vivo molecular imaging of cancer .....                 | 76        |
| Circulating cancer cells in blood as biomarkers of cancer .....               | 76        |
| Array CGH for biomarker discovery in cancer .....                             | 77        |
| <b>Genetic biomarkers .....</b>   | <b>77</b> |
| <b>8. Applications of Cytogenetics .....</b>                                  | <b>78</b> |
| <b>Introduction .....</b>   | <b>78</b> |
| <b>Applications of cytogenetics in research .....</b>                         | <b>78</b> |
| Cytogenetics of embryonic stem cells .....                                    | 78        |
| <b>Genetic disorders .....</b>  | <b>79</b> |
| Technologies for diagnosis of genetic disorders .....                         | 79        |
| Cytogenetic microarrays for diagnosis of mental retardation .....             | 79        |
| Detection of copy number variations in genetic disorders .....                | 80        |
| Detection of non-recurrent DNA rearrangements by aCGH .....                   | 80        |
| Quantitative fluorescent PCR .....  | 81        |
| Representational oligonucleotide microarray analysis .....                    | 81        |
| SignatureChip®-based diagnostics for cytogenetic abnormalities .....          | 81        |
| Screening for cytogenetic abnormalities .....                                 | 82        |
| Cytogenetics in prenatal diagnosis .....                                      | 82        |
| aCGH for prenatal diagnosis .....   | 82        |
| BAC HD Scan test .....  | 83        |
| FISH for prenatal diagnosis .....   | 83        |
| PCR for prenatal diagnosis of trisomy 21 .....                                | 83        |
| Plasma DNA sequencing to detect fetal chromosomal aneuploidies .....          | 84        |
| Concluding remarks and future prospects of prenatal diagnosis .....           | 86        |
| Cytogenetics in preimplantation genetic diagnosis .....                       | 86        |
| Array CGH for PGD .....   | 87        |
| Fluorescent PCR for PGD .....   | 87        |
| FISH for PGD .....  | 87        |
| PGD using whole genome amplification .....                                    | 88        |
| Conditions detected by preimplantation cytogenetic diagnosis .....            | 89        |
| The future of preimplantation genetic diagnosis .....                         | 89        |
| <b>Disorders of the nervous system .....</b>                                  | <b>90</b> |
| Application of cytogenetics in epilepsy .....                                 | 90        |
| Neuropsychiatric disorders in children .....                                  | 90        |
| <b>Cardiovascular disorders .....</b>   | <b>91</b> |
| <b>Infections .....</b>   | <b>91</b> |
| PNA-FISH for diagnosis of infections .....                                    | 91        |
| Diagnosis of bacterial infections at single molecule level .....              | 92        |
| Detection of single virus particles .....                                     | 92        |
| <b>Role of cytogenetics in drug discovery and development .....</b>           | <b>92</b> |
| <b>Role of cytogenetics in the development of personalized medicine .....</b> | <b>93</b> |
| Relation of cytogenetics to personalized medicine .....                       | 93        |
| Cytomics as a basis for personalized medicine .....                           | 94        |
| Molecular imaging and personalized medicine .....                             | 94        |
| Cytogenetics for gender determination .....                                   | 95        |
| Gender determination in competitive sport .....                               | 95        |
| Gender determination in forensic cases .....                                  | 95        |
| <b>Regulatory aspects of FISH .....</b>                                       | <b>95</b> |
| <b>9. Cancer Cytogenetics .....</b>   | <b>98</b> |
| <b>Cancer genetics .....</b>  | <b>98</b> |
| Cytogenetic abnormalities in cancer .....                                     | 98        |
| <b>Cytogenetic technologies for molecular diagnosis of cancer .....</b>       | <b>98</b> |

|  |                |
|--|----------------|
| Applications of aCGH in oncology .....   | 99             |
| Cytogenetics of tumor cells in body fluids.....                                | 100            |
| Cytogenetics and microRNAs .....   | 100            |
| FISH-based techniques .....  | 101            |
| <i>FISH on paraffin-embedded tissues</i> .....                                 | 101            |
| <i>High-throughput Imaging Position Mapping</i> .....                          | 101            |
| Gene expression profiles predict chromosomal instability in tumors.....        | 101            |
| Loss of heterozygosity .....   | 102            |
| Molecular Combing for cancer diagnosis.....                                    | 102            |
| Mutation detection at molecular level .....                                    | 102            |
| Proteomic identification of oncogenic chromosomal translocation partners ..... | 103            |
| SNPs and cytogenetics.....   | 103            |
| Tissue microarrays for cancer diagnosis .....                                  | 103            |
| <b>Applications of cytogenetics in molecular diagnosis of cancer .....</b>     | <b>104</b>     |
| Molecular cytogenetics in hematological malignancies.....                      | 104            |
| <i>Chromosome translocations in leukemias</i> .....                            | 105            |
| <i>Cytogenetics diagnostics for leukemia</i> .....                             | 105            |
| <i>Cytogenetics of acute myeloid leukemia</i> .....                            | 106            |
| <i>Detection of p53 deletions in chronic lymphocytic leukemia</i> .....        | 106            |
| <i>Cytogenetics of lymphomas</i> .....   | 107            |
| <i>Cytogenetics of myelodysplastic syndrome</i> .....                          | 107            |
| <i>Next generation sequencing and MDS</i> .....                                | 108            |
| <i>Cytogenetics of plasma cell myeloma</i> .....                               | 108            |
| Bladder cancer .....   | 108            |
| Bone and soft tissue tumors .....  | 109            |
| Brain tumors .....   | 110            |
| Breast cancer .....  | 111            |
| <i>Chromosomal aberrations in breast carcinomas</i> .....                      | 111            |
| <i>FISH vs CISH and SISH for determining of HER-2/neu amplification</i> .....  | 111            |
| <i>Genomic profiles of breast cancer</i> .....                                 | 112            |
| Colorectal cancer .....  | 112            |
| Lung cancer .....  | 113            |
| Ovarian cancer .....   | 113            |
| <i>aCGH analyses of cisplatin-resistant ovarian cancer cells</i> .....         | 113            |
| Prostate cancer.....   | 114            |
| Renal cancer .....   | 114            |
| Thyroid cancer.....  | 115            |
| <b>Cytogenetics-based anticancer strategies.....</b>                           | <b>115</b>     |
| aCGH-based strategies for targeting cancer pathways .....                      | 115            |
| Allele-specific inhibition .....   | 115            |
| Prognostic and therapeutic significance of gene amplifications .....           | 116            |
| RNAi-based approach for leukemia .....   | 116            |
| Significance of double minutes .....   | 116            |
| <b>Online resources for cancer cytogenetics .....</b>                          | <b>117</b>     |
| <b>The Cancer Genome Atlas .....</b>   | <b>117</b>     |
| <b>Concluding remarks on cancer cytogenetics .....</b>                         | <b>117</b>     |
| <br><b>10. Cytogenetics Markets.....</b>                                       | <br><b>120</b> |
| Introduction .....   | 120            |
| Methods for study of cytogenetic markets .....                                 | 120            |
| Cytogenetic markets according to technologies.....                             | 120            |
| Market for FISH technologies.....  | 121            |
| Array CGH markets .....  | 121            |
| Sorting the markets of overlapping technologies.....                           | 122            |
| Markets for cytogenetics according to therapeutic areas.....                   | 122            |
| Geographical distribution of markets for cytogenetics.....                     | 124            |
| SWOT of competing technologies.....  | 124            |
| Unfulfilled needs.....   | 125            |
| Limitations of current technologies .....                                      | 127            |
| Promising future developments in cytogenetics.....                             | 127            |
| Commercial aspects of genome sequencing technologies .....                     | 127            |
| <i>Cost of genotyping</i> .....  | 127            |
| <br><b>11. Companies .....</b>   | <br><b>130</b> |
| Profiles of companies.....   | 130            |
| Collaborations.....  | 218            |
| <br><b>12. References.....</b>   | <br><b>222</b> |

## Tables

|  |     |
|--|-----|
| Table 1-1: Historical landmarks in the evolution of cytogenetics .....                       | 12  |
| Table 2-1: A classification of technologies used for cytogenetics .....                      | 24  |
| Table 3-1: Classification and scope of FISH and related technologies.....                    | 31  |
| Table 3-2: A selection of companies with FISH diagnostics.....                               | 41  |
| Table 4-1: Microarray/biochip-based technologies for cytogenetics .....                      | 42  |
| Table 4-2: Chromosomal structural abnormalities detected by CGH.....                         | 46  |
| Table 4-3: Companies with whole genome chips/microarrays .....                               | 51  |
| Table 5-1: Companies involved in developing molecular imaging .....                          | 58  |
| Table 5-2: Technologies for single molecule detection .....                                  | 59  |
| Table 6-1: Nanobiotechnologies for single molecule detection.....                            | 69  |
| Table 7-1: Types of cancer biomarkers relevant to cytogenetics .....                         | 75  |
| Table 8-1: Applications of cytogenetics.....   | 78  |
| Table 8-2: Application of preimplantation cytogenetic diagnosis in monogenic disorders ..... | 89  |
| Table 9-1: WHO classification of myelodysplastic syndromes.....                              | 108 |
| Table 9-2: Fusion genes in malignant bone and soft tissue tumors .....                       | 109 |
| Table 9-3: Fusion genes in adenocarcinoma of the thyroid .....                               | 115 |
| Table 10-1: Cytogenetic markets according to technologies from 2020-2030 .....               | 120 |
| Table 10-2: Market size for cytogenetics according to applications 2020-2030.....            | 122 |
| Table 10-3: Global cytogenetics markets 2020-2030 .....                                      | 124 |
| Table 10-4: SWOT of conventional FISH .....  | 124 |
| Table 10-5: SWOT of innovative FISH technologies .....                                       | 125 |
| Table 10-6: SWOT of PCR-based assays .....   | 125 |
| Table 10-7: SWOT of aCGH.....  | 125 |
| Table 10-8: SWOT of single molecule imaging .....  | 125 |
| Table 11-1: Major suppliers of reagents/services/equipment for cytogenetics.....             | 130 |
| Table 11-2: Major consumers of reagents .....  | 131 |
| Table 11-3: Companies developing innovative technologies in cytogenetics.....                | 131 |
| Table 11-4: Collaborations in cytogenetics .....   | 218 |

## Figures

|  |     |
|--|-----|
| Figure 6-1: Scheme of a novel optical mRNA biosensor .....                             | 72  |
| Figure 8-1: Relation of various technologies to drug discovery and development .....   | 93  |
| Figure 8-2: Relation of cytogenetics to personalized medicine .....                    | 93  |
| Figure 8-3: Relation of cytomics to personalized medicine.....                         | 94  |
| Figure 9-1: Basic scheme of genome-wide screening techniques for cancer.....           | 98  |
| Figure 10-1: Distribution of applications of cytogenetics in the year 2025 .....       | 123 |
| Figure 10-2: Distribution of applications of cytogenetics in the year 2030 .....       | 123 |
| Figure 10-3: Unfulfilled needs in cytogenetics according to technologies .....         | 126 |
| Figure 10-4: Unfulfilled needs in cytogenetics according to areas of application ..... | 126 |